viral hepatitis industry size, viral hepatitis market trends, viral hepatitis market analysis, viral hepatitis market forecast, viral hepatitis market opportunities, viral hepatitis market drivers
What are the recent trends in market size and growth for the viral hepatitis market?
The viral hepatitis market size has grown steadily in recent years. It will grow from $16.21 billion in 2024 to $16.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to vaccine development, blood screening programs, antiviral drugs, global health initiatives.
The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $19.97 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to access to treatment, public health legislation, combination therapies, health equity initiatives. Major trends in the forecast period include personalized treatment plans, digital health tools, ai in disease monitoring, hepatitis c micro-elimination.
Get Your Free Sample of The Global Viral Hepatitis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp
How have varous drivers impacted the growth of the viral hepatitis market?
The rising prevalence of hepatitis is expected to propel the growth of the viral hepatitis market going forward. Hepatitis is an infection of the liver caused by several infectious viruses and non-infectious substances, which can result in several medical issues. Hepatitis A, B, C, D and E are among the viruses that can cause viral hepatitis, which results in liver inflammation and damage. For instance, in April 2024, according to the European Centre for Disease Prevention and Control, a Sweden-based government health agency, there were 28,855 recorded cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, an increase of 78% compared to 16,187 cases in 2021. Additionally, the number of cases in 2022, totaling 28,420, represents a crude rate of 8.5 cases per 100,000 people. Therefore, the rising prevalence of hepatitis will drive the viral hepatitis market.
What are the primary segments of the viral hepatitis market?
The viral hepatitis market covered in this report is segmented –
1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis
3) By Treatment: Antiviral Drugs, Surgery, Vaccine, Immune Modulator Drugs, Other Treatments
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Hepatitis A: Acute Hepatitis A, Chronic Hepatitis A
2) By Hepatitis B: Acute Hepatitis B, Chronic Hepatitis B, Hepatitis B Carrier
3) By Hepatitis C: Acute Hepatitis C, Chronic Hepatitis C
4) By Other Disease Types: Hepatitis D, Hepatitis E
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report
Which firms are leading the viral hepatitis market?
Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.
How will industry trends affect the trajectory of the viral hepatitis market?
Companies operating in the viral hepatitis market are working on advancing new drugs and development to sustain their position in the market. Drug development and innovation boost scientific understanding by giving insights into disease mechanisms and accelerating the development of new treatments. For instance, in November 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced that the Food and Drug Administration (FDA) had granted the supplemental new medicine application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets as a once-daily medication to treat chronic hepatitis B virus (HBV) infection in children 12 years of age and older with compensated liver disease. The 24-week Phase 2 clinical trial results supported Vemlidy’s approval in this group of pediatric patients.
Which geographic trends are shaping the viral hepatitis market, and which region has the highest market share?
North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Viral Hepatitis Market Report 2025 Offer?
The viral hepatitis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Viral hepatitis refers to a group of infectious diseases caused by different viruses (hepatitis A, B, C, D and E), which primarily affect the liver. The symptoms can vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting and fever.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13028
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
